Yazar "Keskin, İlknur" seçeneğine göre listele
Listeleniyor 1 - 4 / 4
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe A different view on the platelet aggregation inhibitor clopidogrel - a well-suitable anti-oedema agent in a preclinical model of brain injury?(Czech Medical Soc, 2019) Günal, Mehmet Yalçın; Yuluğ, Burak; Çağlayan, Berrak; Ozansoy, Mehmet; Kılıç, Ülkan; Keskin, İlknur; Kılıç, ErtuğrulAim: The neuroprotective effects of clopidogrel have already been shown in various experimental models. Taking into account the fact that clopidogrel is well tolerated and approved for use in various clinical settings, it can be an attractive candidate for further clinical investigations, especially when the anti-oedema effect appears to be a reasonable adjuvant strategy, such as in brain injury (BI). Here we aimed to examine the neuroprotective role of clopidogrel in BI. Methods: To investigate the effects of clopidogrel, we induced BI in mice using a cold trauma model and evaluated the underlying cell survival/death mechanisms via cresyl violet, TUNEL staining and western blot analysis. Results: Clopidogrel at a dose of 3 mg/kg led to a significant reduction in brain swelling. Similar decreases were observed with 10 mg/kg and 30 mg/kg of clopidogrel. We also have shown that clopidogrel blocks the prominent inflammatory injury pathways and exerts a significant anti-apoptotic effect (3 and 30 mg/kg), which has boon associated with increased neuronal cell survival pathways. Clopidogrel (3, 10 and 30 mg/kg) dose-dependently altered the JNK, p-38, AKT, ERK and p53 levels. Conclusion: Our findings demonstrate that clopidogrel can be a novel candidate for the reduction of post-traumatic BI and oedema. We propose that it can be applied mainly in the acute phases of cerebral ischaemia, which is characterized by haemorrhagic transformation and brain oedema.Öğe Combined therapy with probiotic VSL#3 and Omega-3 fatty acids attenuates colonic injury and inflammation in chronic DNBS-induced colitis in mice(2022) Yoldaş İlktaç, Havvanur; Kızıltan, Gül; Lanpir, Aslı Devrim; Ozansoy, Mehmet; Günal, Mehmet Yalçın; Özmen Togay, Sine; Keskin, İlknur; Özdemir, Ekrem M.; Kılıç, UlkanWe published the abovementioned article about probiotic mixture VSL#3 on October 6, 2021. Since the product was named VSL#3 in our purchasing process in early 2016, it is referred to as VSL#3 in our article. In addition, the product currently known as VSL#3 is not the same as De Simone Formulation. De Simone Formulation is now available as Visbiome® in the United States and Vivomixx® in Europe. The authors would like to apologise for any inconvenience causedÖğe Role of erythropoietin and its receptor in the development of endometriosis in rats(2019) Günal, Mehmet Yalçın; Ozansoy, Mehmet; Kılıç, Ülkan; Keskin, İlknur; Özdemir, Ekrem Musa; Aslan, İsmail; Kılıç, ErtuğrulObjective: Besides its hematopoietic function, erythropoietin (EPO) may protect tissues from degenerative disorders. As such, EPO and its receptors were revealed in nonhematopoietic cells, including stromal and endometrial epithelial cells. However, the role of EPO in endometrial disorders is still unknown. Here, we aimed to examine the role of EPO and its receptor activation in the development of endometriosis in rats. Material and Methods: Animals were treated with EPO, darbepoietin (the synthetic form of EPO) or EPO’s receptor activator, methoxy polyethylene glycol-epoetin beta (MIRCERA), after development of endometriosis. Endometriosis was induced by estrogen-administration following surgical attachment of endometrial surface on the inner abdominal wall. Treatments were started 3 weeks after induction of endometriosis and continued for the following 3 weeks. For the analysis of recurrence of endometriosis, additional analyses were conducted 3 weeks after cessation of treatments. Results: As compared with vehicle-treated animals, lesion size was reduced significantly and recurrence of endometriosis was not observed in all treatment groups. Histopathologic examination revealed that EPO and darbepoietin were more effective than MIRCERA- and vehicle-treated animals. Conclusion: Here we provide evidence that EPO is a promising candidate for the treatment of endometriosis. Our histopathologic results in particular indicate that EPO is more effective than its receptor activator MIRCERA in the development endometriosis. (J Turk Ger Gynecol Assoc 2019; 20: 41-6)Öğe The effect of probiotic and omega-3 supplements on total oxidant and total antioxidant levels in experimental colitis(2021) İlktaç, Havvanur Yoldaş; Kızıltan, Gül; Ozansoy, Mehmet; Kılıç, Ülkan; Togay, Sine Özmen; Keskin, İlknur; Özdemir, Ekrem Musa; Günal, Mehmet YalçınObjective: Treatment of inflammatory bowel disease (IBD) usually involves medical therapy. For this reason, it is recommended to seek alternative treatment methods such as nutritional therapy. The aim of the study is to evaluate the effects of probiotics and omega-3 fatty acids on total oxidant and total antioxidant levels in an experimental colitis model. Methods: Mice were randomly divided into five groups (n= 10/group) as healthy group, colitis group, group treated with probiotics (VSL#3), group treated with omega-3 (w-3), and group treated with both probiotics and omega-3. To induce experimental colitis, 200 mg/kg dinitrobenzene sulfonic acid (DNBS) + 30% ethanol combination was rectally administered to anesthetized mice. Total oxidant (TOS) and total antioxidant (TAS) levels were measured at the tissue level. Results: Lower concentrations of TOS were observed in the probiotics groups (2.11 +/- 0.23 mmol H2O2 Eq/L), probiotics+omega-3 (2.56 +/- 1.18 mmol H2O2 Eq/L), and omega-3 (3.02 +/- 1.88 mmol H2O2 Eq/L) groups compared to the colitis group (3.11 +/- 0.91 mmol H2O2 Eq/L) (p>0.05). Higher TOS and TAS level were observed in the control colitis group compared to other groups; however, the differences were not statistically significant. Conclusion: Our findings showed that TAS and TOS levels were positively affected by the use of probiotic supplements in IBD. It was determined that using w-3 alone was ineffective in decreasing TOS levels. Studies with higher dosages and longer treatment periods are needed to better observe the effects of nutritional supplements on TOS and TAS parameters in inflammatory bowel diseases.
